Gross Profit Comparison: Vertex Pharmaceuticals Incorporated and Bausch Health Companies Inc. Trends

Vertex vs. Bausch: A Decade of Gross Profit Trends

__timestampBausch Health Companies Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 20146008900000519428000
Thursday, January 1, 20157853800000906794000
Friday, January 1, 201670630000001491717000
Sunday, January 1, 201761760000002213533000
Monday, January 1, 201860290000002638058000
Tuesday, January 1, 201962510000003615063000
Wednesday, January 1, 202057780000005469383000
Friday, January 1, 202160400000006670200000
Saturday, January 1, 202257600000007850400000
Sunday, January 1, 202361980000008607000000
Monday, January 1, 20249489600000
Loading chart...

Infusing magic into the data realm

A Decade of Gross Profit Trends: Vertex vs. Bausch

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated and Bausch Health Companies Inc. have shown distinct trajectories in their gross profit margins. From 2014 to 2023, Bausch Health's gross profit has seen a modest decline of approximately 3%, starting at around $6 billion and ending at $6.2 billion. In contrast, Vertex Pharmaceuticals has experienced a remarkable growth of over 1,500%, skyrocketing from $519 million in 2014 to $8.6 billion in 2023.

Key Insights

  • Vertex's Growth: Vertex's strategic focus on innovative treatments has paid off, with a consistent upward trend in gross profit.
  • Bausch's Stability: Despite market challenges, Bausch has maintained a relatively stable gross profit, reflecting its resilience.

These trends highlight the dynamic nature of the pharmaceutical sector and the importance of strategic innovation and stability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025